Skip to main content
. Author manuscript; available in PMC: 2009 Jun 1.
Published in final edited form as: Gastroenterology. 2008 Feb 17;134(7):1927–1937.e2. doi: 10.1053/j.gastro.2008.02.033

Figure 1. Increased PD-1 expression in circulating HCV-specific CD8 T-cells from viremic patients with acute and chronic but not resolved hepatitis C.

Figure 1

(A) %PD-1 expression in CD8 and CD4 T-cells in 10 acute (A), 27 chronic (C) and 8 resolved (R) patients with HCV infection, and 12 healthy HCV-seronegative (H) controls. Median %PD-1+/CD8 T-cells: A15.4% vs. C6.8% vs. R7.5% vs. H6.6% (p=0.006). Median %PD-1+/CD4 T-cells: A8.5% vs. C5.8% vs. R5.7% vs. H6.4% (p=0.47). (B) %Tetramer+ CD8 T-cells specific for HCV (circle), EBV (triangle), and Flu (diamond) in 7 Acute, 19 Chronic, 8 Recovered and 3 Healthy patients. Median %HCV-specific (A0.00% vs. C0.00% vs. R0.08%, p=0.018); Median %EBV or Flu-specific (A0.11% vs. C0.10% vs. R0.04% vs. H0.08, p=0.68). (C) Representative PD-1 stainings for peripheral HCV- and Flu-specific tetramer+ CD8 T-cells from acute, chronic and recovered patients. Top panel shows the PD-1 cutoff strategy with isotype control (dotted red line). (D) %PD-1+ per tetramer+ CD8 T-cells (circle, NS3 1073; diamond, NS3 1406; triangle, NS5B 2594), EBV (filled triangle) and Flu (filled diamond) in 7 acute, 19 chronic, 8 resolved and 3 healthy individuals. Median %PD-1+: HCV-specific CD8 T-cells (A87.4% vs. C26.7% vs. R5.1%, p<0.0001); non-HCV-specific CD8 T-cells (A11.1% vs. C6.5% vs. R11.8% vs. H11.8%, p=0.50). Red horizontal bars indicate the medians. P-values were determined by the Kruskal-Wallis test.